Mavupharma is a Kirkland, Wash.-based drug discovery and development company focused on orally bioavailable, non-nucleotide modulators of the STING (stimulator of interferon genes) pathway. The company is led by Michael Gallatin, Ph.D., president, and Greg Dietsch, Ph.D. Mavupharma aims to develop therapies to treat cancer and infectious diseases using its STING-targeting small molecules. It secured new capital to advance its programs and intends to use the funds to move its lead drug candidates into the clinic. As part of its corporate leadership changes tied to the financing, Bob Baltera of Cirius Therapeutics will join as executive chairman. Financial details reported indicate the company completed a Series A financing to support these near-term clinical plans.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2017